dr. ramalingam on avelumab plus lorlatinib in nsclc
Published 6 years ago • 342 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
2:15
dr. ramalingam on pembrolizumab and chemotherapy in nsclc
-
1:19
dr. ramalingam on emerging combination regimens in nsclc
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
2:16
dr. shaw discusses efficacy of lorlatinib in alk nsclc
-
1:43
dr. ramalingam discusses the results of the phase iii revel study in nsclc
-
2:04
dr. ramalingam discusses the utility of tecemotide in nsclc
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
2:22
dr. ramalingam on plasma egfr mutations as a predictor of response in nsclc
-
1:28
dr. paik on the potential approval of lorlatinib for patients with alk-positive nsclc
-
1:17
dr. bazhenova on the potential approval of lorlatinib for patients with alk-positive nsclc
-
0:59
dr. ramalingam on next steps with nivolumab/ipilimumab in nsclc
-
18:06
lorlatinib in management of alk rearranged nsclc | dr kumar prabhash #iconpune hematology | oncology
-
1:21
dr. suresh s. ramalingam on optimizing immunotherapies in lung cancer
-
2:04
dr. shaw discusses lorlatinib in lung cancer
-
2:00
dr. ramalingam discusses hsp90 as treatment for lung cancer
-
15:35
dr shivam shingla | lorlatinib as front line option in alk mnsclc
-
6:00
ramucirumab plus pembrolizumab improves os in advanced nsclc